Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Liver Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
13 drugs · 38 active trials
14 drugs · 333 active trials
Outside the funnel: Phase not stated 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lenvatinib | Approved | Phase 4 | 65 | 36 | 29 | 134 | 1 | US | Feb 13, 2015 | Jul 24, 2009 |
| Bevacizumab | Approved | Phase 4 | 62 | 33 | 22 | 125 | 1 | US | Feb 26, 2004 | 2003-02 |
| Durvalumab | Approved | Phase 3 | 46 | 24 | 9 | 65 | 1 | US | May 1, 2017 | Oct 19, 2015 |
| Atezolizumab | Approved | Phase 4 | 44 | 20 | 17 | 66 | 1 | US | May 18, 2016 | Sep 5, 2017 |
| Tremelimumab | Approved | Phase 3 | 27 | 13 | 7 | 35 | 1 | US | Oct 21, 2022 | 2008-12 |
| Nivolumab | Approved | Phase 3 | 21 | 13 | 7 | 70 | 1 | US | Dec 22, 2014 | Oct 30, 2012 |
| Pembrolizumab | Approved | Phase 3 | 21 | 10 | 6 | 67 | 1 | US | Sep 4, 2014 | Jul 17, 2014 |
| Cabozantinib | Approved | Phase 3 | 15 | 8 | 3 | 30 | 1 | US | Apr 25, 2016 | Oct 30, 2012 |
| Sorafenib | Approved | Phase 4 | 12 | 3 | 49 | 165 | 1 | US | Dec 1, 2005 | 2002-08 |
| Ipilimumab | Approved | Phase 3 | 10 | 9 | 4 | 24 | 1 | US | Mar 25, 2011 | Oct 30, 2012 |
| Regorafenib | Approved | Phase 3 | 10 | 4 | 3 | 24 | 1 | US | Sep 27, 2012 | May 14, 2013 |
| Sorafenib Tosylate | Approved | Phase 3 | 0 | 0 | 5 | 26 | 1 | US | Dec 1, 2005 | 2005-10 |
| Ramucirumab | Approved | Phase 3 | 0 | 0 | 1 | 7 | 1 | US | Apr 21, 2014 | 2008-02 |
| Futibatinib | Approved | Phase 2 | 0 | 0 | 0 | 1 | 1 | US | Sep 30, 2022 | Aug 17, 2021 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.